Lupron
Author: Zachary McLellan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Lupron (leuprolide; Takeda/AbbVie) is a gonadotropin-releasing hormone (GnRH) agonist which acts on the pituitary gland in the brain to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.” With continued use, GnRH agonists such as Lupron cause downregulation of GnRH receptors in the pituitary gland, generating a significant reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration where levels of the hormone drop by up to 95% and tumor growth is significantly reduced.
TABLE OF CONTENTS
4 Product Profiles
4 Lupron : Prostate cancer
LIST OF FIGURES
6 Figure 1: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
7 Table 1: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Biosimilars Market Access in the EU 
Sign up to the